Get Flat 15% Discount on ED Drugs for orders value $70 or more
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Novartis > February 20, 2012

      US FDA Approves Novartis' Gleevec Drug Label Change

      Novartis announces the US Food and Drug Administration (FDA) approval of the label change for its anti-cancer drug Gleevec (Imatinib Mesylate) to treat CD117-positive gastrointestinal stromal tumor (GIST) patients after surgery. A recent clinical study showed better results such as 54% recurrence-free survival and 55% reduced death risk in gastrointestinal cancer patients with 36 months of Gleevec treatment compared to 12 months of Gleevec treatment.

      With nearly 6000 new cases of GIST reported annually (according to Novartis), FDA’s approval of expanded use of Gleevec drug will help GIST patients to effectively manage the disease.


      Share this Article!

    Back to top^